文献速递神经肿瘤

转移性脑肿瘤激光间质热疗的结局与患者选择原则:多中心机构病例系列

Outcomes and Principles of Patient Selection for Laser Interstitial Thermal Therapy for Metastatic Brain Tumor Management: A Multisite Institutional Case Series.
PubMed 文献 · World Neurosurg · 2022-06-26

该多中心病例系列纳入23例经激光间质热疗(LITT)治疗的转移性脑肿瘤患者,多数为单发(21例)已放疗病灶进展和/或放射性坏死。随访期间81.8%(18例)实现局部控制,56.5%(13例)存活,中位生存期16个月(IQR 12-48.5个月)。

要点

  • LITT治疗转移性脑肿瘤或放射性坏死,81.8%(18例)随访期内实现局部控制。
  • 23例中13例(56.5%)研究结束时存活,中位生存期16个月(IQR 12-48.5个月)。
  • 10例死亡中5例死于治疗病灶以外的中枢神经系统进展。

核心结论

  • LITT治疗影像学进展的转移性中枢神经系统疾病,81.8%的患者获得持续局部控制。

研究设计与样本

  • 多中心机构病例系列,纳入3个Mayo Clinic中心经国际疾病分类第九版和第十版编码识别的恶性脑肿瘤LITT治疗患者,随访至少6个月。
  • 共23例患者,治疗单发(21例)或多发(2例)既往放疗后转移灶进展和/或放射性坏死。
  • 中位年龄56岁(四分位距47-66.5岁)。

主要发现

  • 局部控制基于影像学和临床证据,18例(81.8%)在随访期内实现局部控制,1例无局部控制数据。
  • 研究结束时13例(56.5%)存活;10例死亡中5例死于治疗病灶以外的中枢神经系统进展,无其他患者死于治疗疾病。
  • 该队列中位生存期尚未达到,目前LITT后中位生存期为16个月(四分位距12-48.5个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Laser interstitial thermal therapy (LITT) is an emerging treatment modality for both primary brain tumors and metastases. We report initial outcomes after LITT for metastatic brain tumors across 3 sites at our institution and discuss potential strategies for optimal patient selection and outcomes. METHODS: International Classification of Diseases, Ninth Revision and Tenth Revision codes were used to identify patients with malignant brain tumors treated via LITT across all 3 Mayo Clinic sites with at least 6 months follow-up. Local control was based on radiologic and clinical evidence. Overall survival was measured from time of receiving LITT until death or end of the study period. RESULTS: Twenty-three patients were treated for progression of a single (n = 21) or multiple (n = 2) previously radiated metastatic lesions and/or radiation necrosis. Median age was 56 years (interquartile range, 47-66.5 years). LITT achieved local control of the lesion in most patients with metastatic tumors or radiation necrosis (n = 18; 81.8%) for the duration of follow-up. One patient did not have local control data available. Thirteen (56.5%) patients remained alive at the end of the study period. No other patients died of their treated disease during the study period; 5 of 10 deaths were attributable to central nervous system progression outside the treated lesion. Although median survival for this cohort has not yet been reached, the current median survival is 16 months (interquartile range, 12-48.5 months) after LITT for metastatic/radiation necrosis lesions. CONCLUSIONS: LITT was associated with sustained local control in 81.8% of patients treated for radiographic progression of metastatic central nervous system disease.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Riviere-Cazaux C, Bhandarkar AR, Rahman M, et al. Outcomes and Principles of Patient Selection for Laser Interstitial Thermal Therapy for Metastatic Brain Tumor Management: A Multisite Institutional Case Series. World Neurosurg. 2022. PMID: 35760326. doi:10.1016/j.wneu.2022.06.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。